Canadian hereditary angioedema guideline
Authors:
- Stephen BetschelSBStephen Betschel
- Jacquie BadiouJBJacquie Badiou
- Karen BinkleyKBKaren Binkley
- Jacques HébertJHJacques Hébert
- Amin KananiAKAmin Kanani
- Paul KeithPKPaul Keith
- Gina LacuestaGLGina Lacuesta
- Emel Aygören-PürsünEAEmel Aygören-Pürsün
- Jonathan BernsteinJBJonathan Bernstein
- Konrad BorkKBKonrad Bork
- Teresa CaballeroTCTeresa Caballero
Open Access
- 24 October 2014
- journal article
- research article
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 10 (1) , 1-18
Abstract
Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries where there are more organized models for HAE management, and where additional therapeutic options are licensed and available for use. The objective of this guideline is to provide graded recommendations for the management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis, long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their advocates, that there will be an improved understanding of the current recommendations regarding management of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE. Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.Keywords
This publication has 88 references indexed in Scilit:
- Per-Attack Reporting of Prodromal Symptoms Concurrent with C1-Inhibitor Treatment of Hereditary Angioedema AttacksAdvances in Therapy, 2012
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodologyBMC Dermatology, 2012
- Safety and efficacy of icatibant self-administration for acute hereditary angioedemaClinical and Experimental Immunology, 2012
- Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): Spanish multi-centre research projectHealth and Quality of Life Outcomes, 2012
- Safety and Efficacy of Physician-Supervised Self-Managed C1 Inhibitor Replacement TherapyInternational Archives of Allergy and Immunology, 2011
- Hereditary AngioedemaNew England Journal of Medicine, 2008
- Going from evidence to recommendationsBMJ, 2008
- Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patientsAnnals of Allergy, Asthma & Immunology, 2008
- An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angio-oedemaClinical and Experimental Immunology, 2007